As bird flu continues to spread among animals in the U.S., KFF’s Tracking Poll on Health Information and Trust finds that the public is more concerned about its impact on food prices than potential health impacts. Trust in the CDC to provide information on bird flu is also divided along partisan lines, and a large…
Novartis malaria drug Coartem has expanded its approval to include babies. The combination drug, originally formulated as a tablet, has a new dose strength and formulation designed for treating newborns and young infants who develop malarial infections. The post Novartis Drug Becomes First Malaria Therapy for Newborns and Infants appeared first on MedCity News.
With Donald Trump returning to the presidency, the future of Medicaid is uncertain. While Medicaid did not receive a lot of attention directly during the campaign, Trump’s first term can shed light on potential changes that could be implemented administratively without Congress.
This ability to closely monitor patients remotely is redefining the standard of care, especially for those managing complex health conditions. RPM technology provides timely insights that allow healthcare teams to intervene early, improve patient outcomes, and reduce the burden on hospital resources. The post How Wearables Are Changing the Way We Monitor Cancer Treatment appeared…
The decade ahead will test our healthcare system like never before. But within these challenges lies an opportunity to create a more accessible, effective, and sustainable healthcare system — if we dare to innovate and adapt to the changing landscape. The post How Technology and Value-Based Models Will Reshape Healthcare by 2035 appeared first on…
This tracker examines Executive Actions taken by the Trump administration that have the potential to impact LGBTQ+ people’s health. It lists the action taken by date, provisions relevant to LGBTQ+ health, and describes potential impact, including litigation challenging these actions.
Pfizer’s inclacumab did not beat a placebo in a Phase 3 test in sickle cell disease. The trial failure comes nearly a year after Pfizer voluntarily withdrew Oxbryta from the market after tests showed higher rates of complications and deaths for that sickle cell disease drug. The post Pfizer Gets Another Dose of Disappointment as…
By integrating industry standards into e-prescribing software, prescribing organizations can reduce errors to improve patient outcomes and lessen the burden of medication-related errors on healthcare systems. Here’s a look at the new National Council for Prescription Drug Programs (NCPDP) Sig Standard aimed at improving prescription accuracy. The post The Key to Solving Medication Errors is…
Since President Donald Trump released his 2026 budget blueprint in early May, calling for $163 billion in federal spending cuts, much of the attention has focused on his slashing of foreign aid and boosting of border security. But the proposal also holds important clues — amid some mixed messages — about the administration’s approach to…
Acclaim Autism’s COO Ryan Cox shares about his team’s tech journey